CapsoVision outlines $1B initial colon opportunity as it targets FDA submission before year-end 2026

• “The third quarter was an important period for CapsoVision. We achieved a major regulatory milestone with FDA clearance of AI Highlights for CapsoCam Plus, completed enrollment for the clinical study supporting our

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.